Say Hello!
Don’t be shy.

0333 323 1843

[email protected]


BioCity Group HQ:
Pennyfoot Street

Bruin Biometrics

Bruin Biometrics

Home > Companies > Bruin Biometrics

About BBI
BBI, LLC, focuses on developing solutions for wound care, orthopedic care and real-time data capture, analytics and reporting.  Leveraging BBI’s passive sensor technology, the company’s portable devices produce actionable data for evidence-based assessments. Innovation at BBI is realized through collaboration between the company’s research and development and clinical teams, where every team member is an expert in his or her respective field. BBI applies rigorous scientific, technical and clinical standards to drive product development and address unmet and urgent clinical needs. BBI is based in Los Angeles and maintains a European office in Manchester, UK.

About the SEM Scanner
SEM Scanner is a hand-held device to detect early-stage pressure ulcers and deep tissue injury (DTI). SEM Scanner uses non-invasive biosensor technology to measure sub-epidermal moisture (SEM), a biophysical marker associated with localized edema in the initial inflammatory phase of pressure ulcer formation. SEM has been found to indicate tissue damage three to ten days before visible symptoms or pressure ulcer formation. The SEM Scanner produces real-time information to clinicians for the objective evaluation of tissue health status. SEM Scanner is CE Mark approved and launched in the UK market in 2014. BBI is working with FDA to make the SEM Scanner available in the US market in 2016


Pressure Damage
Clinicians know that pressure ulcer damage does not magically appear, rather healthy tissue deteriorates to a damaged state that leads to pressure ulcers over a period of time.  Clinicians also know that by the time redness appears, the damage is already done.  The SEM Scanner offers clinicians a tool to detect pressure ulceration before the damage becomes visible at the skin’s surface and therefore can proactively treat them prior to chronic damage occurring. This improvement in the treatment paradigm is transformational to pressure ulcer reversal and prevention, with early detection, more than 80% of pressure ulcers can be prevented.